儿童期起病听力损失的遗传学诊断与人工耳蜗植入结局的关联
该研究在2019至2022年于西雅图儿童医院和华盛顿大学耳鼻咽喉科及听力科门诊开展,纳入449名18岁前起病的双侧感音神经性听力损失儿童(来自406个家庭),进行基因组测序和听力及人工耳蜗效果评估。结果显示52%的家庭获得遗传学诊断,涉及43个不同基因,听力损失严重程度、进展及人工耳蜗植入后言语感知效果因基因型而异。
要点
- 406个家庭中52%获得遗传学诊断,包括55/82个多发家庭和155/324个单发家庭。
- 致病变异涉及43个不同基因,每名儿童(除1例外)仅1个基因存在致病变异。
- 所有植入人工耳蜗的儿童,成人言语感知测试结果均高于植入前水平,但成功程度因基因型差异很大。
核心结论
- 该横断面研究结果表明,遗传学诊断目前已足够先进,可将其整合到儿童期起病听力损失的精准医疗中。
研究设计与样本
- 横断面分析(基因组学)和回顾性队列分析(听力学测量)于2019至2022年在西雅图儿童医院和华盛顿大学耳鼻咽喉科及听力科门诊开展,纳入449名18岁前起病的双侧感音神经性听力损失儿童(来自406个家庭),数据分析于2022年1月至6月进行。
主要发现
- 406个家庭中210个(52%)获得遗传学诊断,包括82个多发家庭中的55个(67%)和324个单发家庭中的155个(48%);不同祖先背景儿童的遗传诊断率相似。
- 致病变异涉及43个不同基因,每名儿童(除1例外)仅1个基因存在致病变异;听力损失严重程度、受累频率和进展因基因而异,对某些基因还因基因内基因型而异。
- 对于MYO6、OTOA、SLC26A4、TMPRSS3致病突变或GJB2严重功能缺失变异的儿童,听力损失呈进行性,每十年损失超过10 dB。
- 所有植入人工耳蜗的儿童,成人言语感知测试结果均高于植入前水平,但成功程度因基因型差异很大。
- 调整植入年龄和植入后间隔时间后,因MITF或TMPRSS3致听力损失儿童的言语感知最高。
关键数值与推荐
- 406名参与者中,208名(51%)为女性,17名(4%)为非裔/非洲裔美国人,32名(8%)为东亚裔,219名(54%)为欧洲裔,53名(13%)为拉丁裔/混血美国人,16名(4%)为南亚裔。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the US, most childhood-onset bilateral sensorineural hearing loss is genetic, with more than 120 genes and thousands of different alleles known. Primary treatments are hearing aids and cochlear implants. Genetic diagnosis can inform progression of hearing loss, indicate potential syndromic features, and suggest best timing for individualized treatment. OBJECTIVE: To identify the genetic causes of childhood-onset hearing loss and characterize severity, progression, and cochlear implant success associated with genotype in a single large clinical cohort. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional analysis (genomics) and retrospective cohort analysis (audiological measures) were conducted from 2019 to 2022 at the otolaryngology and audiology clinics of Seattle Children's Hospital and the University of Washington and included 449 children from 406 families with bilateral sensorineural hearing loss with an onset younger than 18 years. Data were analyzed between January and June 2022. MAIN OUTCOMES AND MEASURES: Genetic diagnoses based on genomic sequencing and structural variant analysis of the DNA of participants; severity and progression of hearing loss as measured by audiologic testing; and cochlear implant success as measured by pediatric and adult speech perception tests. Hearing thresholds and speech perception scores were evaluated with respect to age at implant, months since implant, and genotype using a multivariate analysis of variance and covariance. RESULTS: Of 406 participants, 208 (51%) were female, 17 (4%) were African/African American, 32 (8%) were East Asian, 219 (54%) were European, 53 (13%) were Latino/Admixed American, and 16 (4%) were South Asian. Genomic analysis yielded genetic diagnoses for 210 of 406 families (52%), including 55 of 82 multiplex families (67%) and 155 of 324 singleton families (48%). Rates of genetic diagnosis were similar for children of all ancestries. Causal variants occurred in 43 different genes, with each child (with 1 exception) having causative variant(s) in only 1 gene. Hearing loss severity, affected frequencies, and progression varied by gene and, for some genes, by genotype within gene. For children with causative mutations in MYO6, OTOA, SLC26A4, TMPRSS3, or severe loss-of-function variants in GJB2, hearing loss was progressive, with losses of more than 10 dB per decade. For all children with cochlear implants, outcomes of adult speech perception tests were greater than preimplanted levels. Yet the degree of success varied substantially by genotype. Adjusting for age at implant and interval since implant, speech perception was highest for children with hearing loss due to MITF or TMPRSS3. CONCLUSIONS AND RELEVANCE: The results of this cross-sectional study suggest that genetic diagnosis is now sufficiently advanced to enable its integration into precision medical care for childhood-onset hearing loss.
引用
- Carlson RJ, Walsh T, Mandell JB, et al. Association of Genetic Diagnoses for Childhood-Onset Hearing Loss With Cochlear Implant Outcomes. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 36633841. doi:10.1001/jamaoto.2022.4463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。